Pediatrix Medical Group (NYSE:MD) Earns Hold (C) Rating from Weiss Ratings

Pediatrix Medical Group (NYSE:MD)‘s stock had its “hold (c)” rating restated by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also commented on the company. Leerink Partners lifted their price objective on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, September 5th. Wall Street Zen upgraded Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. UBS Group lifted their price objective on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a “neutral” rating in a research report on Thursday, August 14th. Finally, Zacks Research upgraded Pediatrix Medical Group to a “strong-buy” rating in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and an average price target of $16.79.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $17.12 on Wednesday. The stock has a 50-day moving average price of $16.12 and a 200 day moving average price of $14.48. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 13.27 and a beta of 1.26. Pediatrix Medical Group has a 12 month low of $11.59 and a 12 month high of $18.22.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The firm had revenue of $468.84 million during the quarter, compared to analyst estimates of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The company’s revenue was down 7.1% on a year-over-year basis. During the same period last year, the company earned $0.34 earnings per share. Research analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current year.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MD. GAMMA Investing LLC boosted its holdings in Pediatrix Medical Group by 219.5% during the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company’s stock worth $37,000 after buying an additional 1,765 shares during the last quarter. Marshall & Sullivan Inc. WA bought a new position in Pediatrix Medical Group during the second quarter worth about $41,000. Canada Pension Plan Investment Board bought a new position in Pediatrix Medical Group during the second quarter worth about $83,000. AlphaQuest LLC boosted its holdings in Pediatrix Medical Group by 16.0% during the first quarter. AlphaQuest LLC now owns 5,877 shares of the company’s stock worth $85,000 after buying an additional 811 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Pediatrix Medical Group during the second quarter worth about $99,000. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.